| 日付 |
時間 |
ソース |
タイトル |
|---|
| 2024/5/30 | 00:54 | EDGAR2 | Form SD - Specialized disclosure report |
| 2024/5/18 | 06:22 | EDGAR2 | Form ARS - Annual Report to Security Holders |
| 2024/5/18 | 06:20 | EDGAR2 | Form DEFR14A - Revised definitive proxy soliciting materials |
| 2024/5/14 | 22:00 | GLOBE | Nuwellis Announces Expansion of Ultrafiltration Program to.. |
| 2024/5/09 | 22:00 | GLOBE | Nuwellis Announces Purchase Agreement with a 50 Hospital.. |
| 2024/5/09 | 06:28 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2024/5/09 | 06:26 | EDGAR2 | Form PRER14A - Preliminary Proxy Soliciting materials |
| 2024/5/07 | 21:00 | GLOBE | Nuwellis, Inc. Announces First Quarter 2024 Financial.. |
| 2024/5/02 | 22:00 | GLOBE | Nuwellis Receives USPTO Notice of Patent Allowance for.. |
| 2024/5/01 | 07:09 | GLOBE | Nuwellis Announces Closing of $2.7 Million Public Offering |
| 2024/5/01 | 05:41 | GLOBE | Nuwellis, Inc. To Report First Quarter 2024 Financial.. |
| 2024/4/26 | 22:17 | GLOBE | Nuwellis Announces Pricing of $2.7 Million Public Offering |
| 2024/4/09 | 22:00 | GLOBE | Nuwellis Announces Launch of Ultrafiltration Therapy Using.. |
| 2024/3/12 | 06:08 | EDGAR2 | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 2024/3/07 | 23:08 | GLOBE | Late-Breaking Data Highlighting Benefits of Ultrafiltration.. |
| 2024/3/07 | 02:02 | EDGAR2 | Form 8-K - Current report |
| 2024/3/05 | 22:00 | GLOBE | Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023.. |
| 2024/3/05 | 20:05 | IHMARKETNEWS | U.S. Futures Dip, Crude Oil Fluctuates |
| 2024/2/27 | 23:00 | GLOBE | Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023.. |
| 2024/2/22 | 21:58 | GLOBE | Nuwellis’ Distribution Partner, SeaStar Medical, Receives.. |
| 2024/2/21 | 07:06 | GLOBE | Nuwellis, Inc. Reports Inducement Grants Under Nasdaq.. |
| 2024/2/20 | 22:42 | GLOBE | Nuwellis to Announce Late-Breaking Clinical Data and Host.. |
| 2024/2/09 | 07:19 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
| 2024/2/06 | 23:07 | EDGAR2 | Form 8-K - Current report |
| 2024/2/06 | 23:00 | GLOBE | New Case Series Demonstrates Potential of Aquadex Therapy.. |
| 2024/1/10 | 07:30 | EDGAR2 | Form 8-K/A - Current report: [Amend] |
| 2024/1/08 | 23:24 | EDGAR2 | Form 8-K - Current report |
| 2024/1/05 | 06:25 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 2024/1/05 | 05:05 | GLOBE | Nuwellis Receives FDA Clearance for an Additional Dual Lumen.. |
| 2023/12/14 | 06:05 | EDGAR2 | Form 8-K - Current report |
| 2023/11/28 | 22:00 | GLOBE | New Real-World Data Highlight the Clinical Benefits of.. |
| 2023/11/15 | 06:30 | GLOBE | Nuwellis, Inc. Reports Inducement Grants Under Nasdaq.. |
| 2023/11/08 | 00:00 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2023/11/07 | 22:15 | EDGAR2 | Form 8-K - Current report |
| 2023/11/07 | 22:00 | GLOBE | Nuwellis, Inc. Announces Third Quarter 2023 Financial.. |
| 2023/11/02 | 05:15 | EDGAR2 | Form 8-K - Current report |
| 2023/11/01 | 21:00 | GLOBE | Nuwellis Announces Board of Directors Transition |
| 2023/10/31 | 21:00 | GLOBE | Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA.. |
| 2023/10/19 | 05:15 | GLOBE | Nuwellis, Inc. To Announce Third Quarter 2023 Financial.. |
| 2023/10/18 | 05:30 | EDGAR2 | Form 8-K - Current report |
| 2023/10/18 | 05:15 | GLOBE | Nuwellis Announces Closing of $2.25 Million Public Offering.. |
| 2023/10/13 | 21:30 | GLOBE | Nuwellis Announces Pricing of $2.25 Million Public Offering.. |
| 2023/10/10 | 21:30 | EDGAR2 | Form 8-K - Current report |
| 2023/10/10 | 21:00 | GLOBE | Nuwellis Provides Regulatory Update on SeaStar Medical’s.. |
| 2023/10/07 | 05:50 | EDGAR2 | Form POS462C - Post-effective amendment to registration.. |
| 2023/10/05 | 22:27 | EDGAR2 | Form AW - Amendment Withdrawal Request |
| 2023/10/05 | 06:29 | EDGAR2 | Form POS AM - Post-Effective amendments for registration.. |
| 2023/9/29 | 21:56 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
| 2023/9/12 | 05:15 | GLOBE | Nuwellis to Present at the Gilmartin Group Emerging Growth.. |
| 2023/9/07 | 05:23 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
